CONCEPT NOTE FOR PLENARY SESSION 2

14th Priorities 2024 Conference

Plenary Session 2

The 14th Priorities Conference
Millennium Hilton
Bangkok, Thailand

Title: Early HTA: are we too early to inform priorities?

Date: 8 May 2024

Time: 13:00 – 14:15 (GMT+7)

Session coordinators: Dimple Butani & Thanakit Athibodee

Background:
In the dynamic landscape of Health Technology Assessment (HTA), the concept of 'Early HTA' has emerged as a critical tool for evaluating the potential value of emerging medical products or interventions. However, a pertinent question arises: Are we engaging in early assessment too prematurely to inform healthcare priorities effectively?

The plenary session '***Early HTA: Are we too early to inform priorities?'*** seeks to dissect this important question by exploring the evolving role of early HTA methodologies and prioritization strategies linked to the allocation of budgetary resources for early HTA. As medical innovations continue to accelerate, the urgency to assess their potential impact and value grows. This urgency poses a significant challenge in finding the balance between the evaluation speed and the evidence's robustness necessary for the informed decision-making process. This plenary session will navigate this delicate balance, discussing advancements in early HTA methods, inherent challenges, and issues in applying early HTA.

This session will feature insights from the research and innovation program manager's point of view, shedding light on the intersection of medical innovation and prioritization. Attendees will explore alternative tools and options, drawing comparisons to early HTA, while confronting the challenges and issues encountered in real-world research funding practices.

This session culminates in an engaging open discussion section, facilitating discussions around the future landscape of early HTA and regulatory bodies. Participants will be encouraged to contemplate strategies to support the complexities that lie ahead, fostering a dialogue that encourages reflection on plausible impact and future trends.

Objectives:
- Introduction to early HTA and the current landscape of early HTA
- Examine the encountered challenges in different settings when applying early HTA
- Discuss future trends or anticipated challenges to impact early HTA practices and discuss strategies to navigate these complexities.

Expected output/outcome:

- To increase awareness and consolidate insights from the plenary session on Early HTA, the intended outcome includes the production of a peer-reviewed journal article.
- This article will serve as a documented record of the comprehensive discussions and key findings presented during the session.

Format:

- Presentation and open discussion.
- Participants can post questions throughout the session via the Whova application platform or ask the panelists directly during the open discussion.

Agenda of "Plenary 2 Session" on May 8, 2024: 13:00-14:15 PM.

Time	Particular	Person(s) responsible
13:00 – 13:05 PM	**Early HTA: Are we too early to inform priorities?'** • Open remarks and questions for audiences	Prof. Paula Lorgelly
13:05 – 13:15 PM	**Global view of early HTA and prioritization** • Overview of the global landscape of early HTA • Potentials and limitations	Prof. Maarten IJzerman
13:15 – 13:25 PM	**Early HTA in practices** • Application of early HTA • Role of early HTA in stakeholder engagement with the public, private and policymaker • Challenges and issues of applying early HTA in different settings (i.e., budget allocation)	Assist.Prof. Wang Yi
13:25 – 13:35 PM	**Early HTA through the lens of innovation program manager** • Implication of early HTA on medical innovation and prioritization from a funding program manager perspective • What are other useful tools or assessment options compared to early HTA when allocating budget for innovation technology advancement? • Challenges/issues of early HTA in the real-world practice of research funding	Dr. Maneerat Ekkapongpisit
	Application of early HTA on vaccine development	Dr. Raymond Hutubessy

13:35 – 13:45 PM	• Role of early HTA on vaccine development • The influence of early HTA on real-world data and how it influences the real-world practice on vaccines	
13:45 – 14:15 PM	**Open discussion: Q&A** • Future trends of early HTA • How do we address the foreseeable complexities of early HTA?	All speakers and moderator

Speakers:

Prof. Maarten Ijzerman	
	**Prof. Maarten Ijzerman** is Dean of Erasmus School of Health Policy & Management in the Netherlands and an honorary Professor in the Melbourne School of Population and Global Health, Australia. He has previous experience in Health Technology Assessment as a committee member of MSAC and PBAC (2019-2022) in Australia and as a Chair of the Pharmacoeconomic Guidelines committee (2015-2016) in the Netherlands. He was involved in global taskforces developing methodological guidance for the use of Dynamic Simulation Modelling, Multi-Criteria Decision Making, Constrained Optimisation and Structured Expert Elicitation. Following his PhD in biomedical engineering, he developed an interest in early HTA, a collection of methods and approaches to inform medical product development. In his current research, he is adopting a health systems approach to ensure equitable access to medical technologies, particularly in the field of data-driven, genomics enabled, precision oncology. He is the chair of the Rotterdam Global Health Initiative (RGHI), the chair of ISPOR's Health Sciences Policy Council and a non-executive board member in different organisations. As an academic leader, he is pushing for healthcare researchers to be conscious about labour shortage and the carbon footprint of medical innovation.
Asst. Prof. Wang Yi	
	**Asst. Prof. Wang Yi** is affiliated from the Saw Swee Hock School of Public Health at the National University of Singapore. His research areas include early health technology assessment, traditional health technology assessment, population's preference for health and healthcare, and economic evaluation/analysis using real-world data and observational data. He is also interested in medical innovation and promoting an efficient medical innovation process. He co-directs a research unit, Medical Innovation Development and Assessment Support (MIDAS), to support medical innovation prioritization, development, and adoption in Thailand.

Dr. Maneerat Ekkapongpisit	
	**Dr. Maneerat Ekkapongpisit** joined MORU (Mahidol Oxford Tropical Medicine Research Unit) 4 years ago as a translational partnership manager. Her main role is to set up and manage all aspects of institutional Translation Partnership Awards: Thailand Major Overseas Programme (Thailand iTPA: MOP). Her experiences involved various roles, including top management, research, and operational and Intellectual Property consultants in local and international organizations in both the academic and private sectors. Maneerat got her Doctor of Philosophy degree in molecular genetics and genetic engineering from the international programme at Mahidol University, Thailand, with financial support from the Royal Golden Jubilee scholarship from the Thailand Research Fund. She also got a postdoctoral fellowship from Amedeo Avogadro University of Eastern Piedmont, Italy. She also holds Thai Patent Agent licenses and has a certificated mini-MBA from Chulalongkorn, CBS (Chula Business School). Maneerat is highly passionate and motivated to translate the latest scientific discoveries into practice to improve the community's quality of life.
Dr. Raymond Hutubessy	
	**Dr. Raymond Hutubessy**, a seasoned health economist with over 25 years of experience, is the team lead of the Value of Vaccines, Economics, and Modelling (VoV) team within the World Health Organization (WHO) Department of Immunization, Vaccines, and Biologics (IVB) in Geneva and a visiting Professor at the Saw Swee Hock School of Public Health at the National University of Singapore. He has conducted economic policy research, focusing on non-communicable diseases, vaccine impact, and modelling of vaccine-preventable diseases in both low and high-income countries. Additionally, he is the executive secretary of the WHO Immunization and Vaccine-related Implementation Research (IVIR) Advisory Committee and until recently he was seconded to the G20 Joint Finance and Health Task Force on pandemic response, preparedness and response Secretariat hosted at the WHO.

Moderator:

Prof. Mark Jit	
	**Prof. Mark Jit** is professor of vaccine epidemiology and head of the Department of Infectious Disease Epidemiology at the London School of Hygiene & Tropical Medicine (LSHTM). He also holds visiting professorial appointments at the NUS Saw Swee Hock School of Public Health and the School of Public Health, University of Hong Kong. His research group focuses on epidemiological and economic modelling of vaccines to support evidence-based public health decision making. He also organises or contributes to academic and professional courses on vaccine modelling, economics and decision science around the world.